PDF(1294 KB)
聚乙二醇化重组人粒细胞集落刺激因子在儿童急性淋巴细胞白血病的药代动力学和药效学的前瞻性对照研究
杨文钰, 刘天峰, 陈晓娟, 郭晔, 李婷, 戚本泉, 刘芳, 常丽贤, 阮敏, 刘晓明, 张丽, 邹尧, 陈玉梅, 竺晓凡
中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (11) : 1172-1177.
PDF(1294 KB)
PDF(1294 KB)
聚乙二醇化重组人粒细胞集落刺激因子在儿童急性淋巴细胞白血病的药代动力学和药效学的前瞻性对照研究
Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial
目的 探讨聚乙二醇化重组人粒细胞集落刺激因子（PEG-rhG-CSF）在儿童急性淋巴细胞白血病（ALL）患者中的药代动力学特征，分析其疗效与安全性。方法 前瞻性纳入拟使用环磷酰胺、阿糖胞苷和6-巯基嘌呤巩固治疗的儿童ALL患者，化疗结束后注射PEG-rhG-CSF（PEG-rhG-CSF组）或重组人粒细胞集落刺激因子（rhG-CSF组）。检测PEG-rhG-CSF血药浓度，同时观察两组患儿的疗效及安全性。结果 共纳入17例（PEG-rhG-CSF组9例，rhG-CSF组8例）ALL患儿。PEG-rhG-CSF组患儿峰浓度（Cmax）为348.2（范围114.7~552.0）ng/mL，达峰时间（Tmax）为48.0（范围12.0~72.0）h，半衰期（t1/2）为14.1（范围11.1~18.1）h。血药浓度曲线符合中性粒细胞介导清除机制。与rhG-CSF组相比，PEG-rhG-CSF组患儿中性粒细胞绝对值恢复正常的时间更早（P < 0.05）。两组患儿中性粒细胞绝对值最低点、中性粒细胞缺乏伴发热发生率、Ⅲ/Ⅳ度粒细胞缺乏发生率、Ⅳ度粒细胞缺乏持续时间、感染发生情况及住院时间差异均无统计学意义（P > 0.05）。两组患儿均未发生骨骼、肌肉酸痛。结论 PEG-rhG-CSF在接受巩固化疗的儿童ALL患者中药代动力学特征符合中性粒细胞介导清除机制，半衰期短，中性粒细胞恢复更快。与rhG-CSF相比，安全性无明显差异。
Objective To study the pharmacokinetic characteristics, clinical effect, and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in children with acute lymphoblastic leukemia (ALL). Methods A prospective study was performed on children with ALL who cyclophosphamide, cytarabine, and 6-mercaptopurine were used for consolidation therapy. PEG-rhG-CSF (PEG-rhG-CSF group) or rhG-CSF (rhG-CSF group) was injected after chemotherapy. The plasma concentration of PEG-rhG-CSF was measured, and clinical outcome and safety were observed for both groups. Results A total of 17 children with ALL were enrolled, with 9 children in the PEG-rhG-CSF group and 8 children in the rhG-CSF group. In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours). The plasma concentration curve of PEG-rhG-CSF was consistent with the mechanism of neutrophil-mediated clearance. Compared with the rhG-CSF group, the PEG-rhG-CSF group had a significantly shorter median time to absolute neutrophil count (ANC) recovery (P < 0.05). There were no significant differences between the two groups in ANC nadir, incidence rate of febrile neutropenia, duration of grade IV neutropenia, incidence rate of infection, and length of hospital stay. No bone pain or muscle soreness was observed in either group (P > 0.05). Conclusions The pharmacokinetic characteristics of PEG-rhG-CSF in children with ALL receiving consolidation chemotherapy are consistent with the mechanism of neutrophil-mediated clearance, with a short half life and fast recovery of ANC, and there are no significant differences in safety between PEG-rhG-CSF and rhG-CSF.
急性淋巴细胞白血病 / 聚乙二醇化重组人粒细胞集落刺激因子 / 药代动力学 / 药效学 / 儿童
Acute lymphoblastic leukemia / Pegylated recombinant human granulocyte colony-stimulating factor / Pharmacokinetics / Pharmacodynamics / Child
[1] Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF):the first 10 years[J]. Blood, 1996, 88(6):1907-1929.
[2] Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors:evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel[J]. J Clin Oncol, 2000, 18(20):3558-3585.
[3] Lally J, Malik S, Whiskey E, et al. Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor:a systematic review[J]. J Clin Psychopharmacol, 2017, 37(4):441-446.
[4] Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor[J]. Drug Metab Rev, 1996, 28(4):625-658.
[5] Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy[J]. Ann Oncol, 2003, 14(1):29-35.
[6] Kubo K, Miyazaki Y, Murayama T, et al. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma[J]. Br J Haematol, 2016, 174(4):563-570.
[7] Brito M, Esteves S, André R, et al. Comparison of effectiveness of biosimilar filgrastim (NivestimTM), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC:a non-interventional cohort study[J]. Support Care Cancer, 2016, 24(2):597-603.
[8] Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim[J]. Clin Pharmacokinet, 2011, 50(5):295-306.
[9] Yang BB, Savin MA, Green M. Prevention of chemotherapy-induced neutropenia with pegfilgrastim:pharmacokinetics and patient outcomes[J]. Chemotherapy, 2012, 58(5):387-398.
[10] National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0[EB/OL]. (2009-05-28)[2020-04-20]. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.
[11] Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy[J]. J Clin Oncol, 2000, 18(13):2522-2528.
[12] Spunt SL, Irving H, Frost J, et al. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients[J]. J Clin Oncol, 2010, 28(8):1329-1336.
[13] 杨晟, 石远凯, 刘鹏, 等. 注射用聚乙二醇化重组人粒细胞集落刺激因子Ⅰ期临床药效学[J]. 中国医学科学院学报, 2006, 28(3):339-344.
[14] Fox E, Widemann BC, Hawkins DS, et al. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas[J]. Clin Cancer Res, 2009, 15(23):7361-7367.
